Welcome to our dedicated page for Bausch + Lomb Corporation SEC filings (Ticker: BLCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bausch + Lomb Corporation (BLCO) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, drawn directly from the EDGAR system. As a Canadian-incorporated issuer with common shares listed on the New York Stock Exchange and the Toronto Stock Exchange, Bausch + Lomb files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with exhibits such as credit agreements, indentures and press releases.
For an eye health company operating in vision care, surgical products and ophthalmic pharmaceuticals, these filings contain detailed information on segment performance, risk factors, capital structure and governance. Recent Form 8-K filings describe material events including secured notes offerings, amendments to the company’s credit and guaranty agreement, creation of new term loan tranches and revolving credit facilities, refinancing of existing borrowings, quarterly financial results, investor day materials and changes in the composition of the board of directors.
Investors can use this page to review Bausch + Lomb’s disclosures on direct financial obligations, covenants, leverage ratios and maturity profiles, as well as governance items such as director appointments, committee assignments and executive compensation arrangements referenced in current reports. Over time, the archive will also include annual 10-K reports and quarterly 10-Q reports, which provide more comprehensive discussions of the company’s business, segments, risk factors and financial statements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the nature of new term loans, secured notes, amendments, results of operations and other reported events. Users can also monitor current reports that reference press releases on topics such as investor day presentations, refinancing transactions and quarterly earnings, using this page as a central source for BLCO’s regulatory history and ongoing disclosure record.
Bausch & Lomb Corp (BLCO) reported that one of its directors acquired additional equity in the company. On 11/14/2025, the director acquired 1,642 common shares at a price of $15.60 per share. Following this transaction, the director beneficially owns 66,556 common shares in total, held directly. An accompanying note explains that the reported amount reflects restricted share units, each representing a contingent right to receive one common share of Bausch + Lomb Corporation.
Bausch & Lomb Corp. director reports equity award under Form 4. A company director acquired 1,402 common shares of Bausch & Lomb Corp. on 11/14/2025, coded as an acquisition and priced at $15.60 per share. After this transaction, the director beneficially owned a total of 71,367 common shares held directly. The new shares are in the form of restricted share units, each representing a contingent right to receive one common share of Bausch & Lomb Corporation.
Bausch + Lomb furnished an update tied to its Investor Day on November 13, 2025. The company announced that the event will cover three-year financial targets, details on pipeline products, and a re-affirmation of previously announced guidance for the fiscal year ending December 31, 2025.
A press release and a slide presentation were posted to the company’s website and furnished as Exhibits 99.1 and 99.2. A webcast and replay are available on the Investor Relations section of the site. The materials are being furnished under Regulation FD and are not deemed filed or incorporated by reference.
Bausch + Lomb reported Q3 2025 results with revenue of $1,281 million, up from $1,196 million a year ago, and operating income of $95 million versus $43 million. The quarter showed a net loss attributable to the company of $28 million (–$0.08 per share) compared to net income of $4 million ($0.01) last year, reflecting higher interest expense and other below‑the‑line items despite stronger operations.
For the first nine months, revenue reached $3,696 million (from $3,511 million) and the company recorded a net loss of $302 million (from $314 million). Cash from operations was $147 million, while investing cash outflows of $267 million included higher capex. Long‑term debt stood at $4,922 million and cash and equivalents at $310 million as of September 30, 2025. Bausch Health owned about 88% of BLCO as of October 22, 2025, and the planned separation remains subject to conditions. Shares outstanding were 354,189,784 as of October 22, 2025.
Bausch + Lomb Corporation furnished an 8-K announcing results of operations for the quarter ended September 30, 2025. The detailed financial information is provided in a press release attached as Exhibit 99.1.
The Item 2.02 information is being furnished and is not deemed filed under the Exchange Act, and it is not incorporated by reference into Securities Act filings. The company’s common shares trade as BLCO on the NYSE and Toronto Stock Exchange.
Bausch + Lomb Corporation reported that its Amended and Restated Director Appointment and Nomination Agreement with the Icahn Group terminated in accordance with its terms after the Icahn Group’s net long position in the common shares of Bausch + Lomb’s parent, Bausch Health Companies Inc., fell below a required threshold. The termination became effective on August 14, 2025.
On the same date, Brett Icahn and Gary Hu, who had joined the board in June 2022 as Icahn Group appointees, resigned from Bausch + Lomb’s board of directors. Mr. Hu also stepped down from the Audit and Risk Committee, the Talent and Compensation Committee, and the Science and Technology Committee. The company stated that their resignations did not result from any disagreement with Bausch + Lomb. On August 18, 2025, the company issued a press release summarizing these changes.